Leukocyte telomere length and mortality risk in patients with type 2 diabetes

作者：Bonfigli Anna Rita^*; Spazzafumo Liana; Prattichizzo Francesco; Bonafe Massimiliano; Mensa Emanuela; Micolucci Luigina; Giuliani Angelica; Fabbietti Paolo; Testa Roberto; Boemi Massimo; Lattanzio Fabrizia; Olivieri Fabiola

来源：Oncotarget, 2016, 7(32): 50835-50844.

DOI：10.18632/oncotarget.10615

• telomere shortening
• type 2 diabetes
• mortality
• aging
• Gerotarget

Leukocyte telomere length (LTL) shortening is found in a number of age-related diseases, including type 2 diabetes (T2DM). In this study its possible association with mortality was analyzed in a sample of 568 T2DM patients (mean age 65.9 +/- 9 years), who were followed for a median of 10.2 years (interquartile range 2.2). A number of demographic, laboratory and clinical parameters determined at baseline were evaluated as mortality risk factors. LTL was measured by quantitative real-time PCR and reported as T/S (telomere-to-single copy gene ratio). Age, gender, creatinine, diabetes duration at baseline, and LTL were significantly different between T2DM patients who were dead and alive at follow-up. In the Cox regression analysis adjusted for the confounding variables, shorter LTL, older age, and longer disease duration significantly increased the risk of all-cause mortality (HR = 3.45, 95%CI 1.02-12.5, p = 0.004). Kaplan-Maier analysis also found a different cumulative mortality risk for patients having an LTL shorter than the median (T/S <= 0.04) and disease duration longer than the median (>10 years) (log-rank = 11.02, p = 0.011). Time-dependent mortality risk stratification showed that T2DM duration and LTL combined was a fairly good predictor of mortality over the first 76 months of follow-up.
In conclusion, LTL combined with clinical parameters can provide additive prognostic information on mortality risk in T2DM patients.

• 出版日期2016-8-9